# **Special Issue**

# Challenges and Future Trends of Nano-Based Drug Delivery System in the Treatment of Bone Diseases

### Message from the Guest Editors

The development of advanced nano-biomaterials and novel pharmacological treatments to effectively treat various bone diseases, including osteoporosis. osteoarthritis, and osteoporotic fractures, presents a substantial challenge for contemporary osteopathology research. Through comprehensive investigations into the molecular and cellular mechanisms underlying bone diseases, the development of targeted therapeutics and advanced drug delivery platforms has emerged as a novel paradigm in the treatment of these conditions. Nanomedicine delivery systems have been extensively utilized within this field, exhibiting exceptional performance. The design and therapeutic application of these delivery systems are advancing rapidly, encompassing areas such as nanomedicine carriers, delivery mechanisms, safety and efficacy evaluations, and the clinical application of nanomedicine materials.

This Special Issue will cover all the advances, challenges, and future perspectives in using nanobased drug delivery system to manage bone diseases (e.g., osteoporosis, osteoarthritis, fracture defect, bone tumors, etc.). Original research articles and reviews are welcome.

### **Guest Editors**

Dr. Xiao Lin

School of Life Science, Northwestern Polytechnical University, Xi'an 710072, China

Dr. Jie Shang

School of Life Science, Northwestern Polytechnical University, Xi'an 710072, China

### Deadline for manuscript submissions

30 September 2025



an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/218096

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



## **About the Journal**

### Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

### **Editor-in-Chief**

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

### **Author Benefits**

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

### **Journal Rank:**

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

